Incyte
INCY124.8605.04% ( +5.990 )
Incyte (INCY)
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Cana...
- Open
- 119.000
- High
- 128.283
- Low
- 118.645
- Prev. Close
- 118.870
- Volume
- 2.19M
- Turnover
- 273.67M
- Avg Price
- 124.756
- Bid/Ask Ratio
- --
- Amplitude
- 8.11%
- 52wk High
- 128.283
- Volume Ratio
- 2.78
- Turnover Ratio
- 1.31%
Incyte Analyst Rating
View MoreForecast & Rating
Jul 28, 2026Price forecast
$115.29-9.07%
Forecast & RatingBuy
25analysts
- Strong buy36.00%
- Buy8.00%
- Hold52.00%
- Sell4.00%
- Strong sell0.00%
News
- Earnings Watch · 5 hours ago
Incyte | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 1.674 B
- benzinga_article · 1 hour ago
James Michael Morrissey Expands Holdings With $54K Incyte Stock Options Acquisition
- benzinga_article · 4 hours ago
ServiceNow, Meta, eBay And A Health Care Stock On CNBC’s ‘Final Trades’
- Quartr · 5 hours ago
INCY: Q2 2026 revenue grew 38% year-over-year, driven by strong sales and a one-time Opzelura benefit
- MarketWatch Automated · 19 hours ago
Incyte Corp. Stock Underperforms Monday When Compared To Competitors Despite Daily Gains
- Stock Story · 1 day ago, 10:04 PM
What To Expect From Incyte’s (INCY) Q2 Earnings
